GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil with revenues of CZK 2,897 mil in 2017, up by 72% and down by 14.6%, respectively, compared to the previous year. This translates into a net margin of 2.26%.
On the operating level, EBITDA reached CZK 97.4 mil, up 56% compared to the previous year. Over the last five years, the company's EBITDA has fallen 16.1% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of CZK 72.9 mil or 2.52% of sales. When investments are excluded, free cash flow reached CZK -80.1 mil, or -2.76% of sales in 2017.
In the last five years, the company generated free cash flow of CZK -230 mil. That compares to a cumulative net profit of CZK 443 mil in the same period.
You can see all the company’s data at GlaxoSmithKline Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
